Table 3.
Enrolment number and publishing timeline for completed studies
| Registration number | Type of study | Treatment | Planned enrolment (n) | Total patients1 (n) | H1N1 patients1 (n) | First patient enrolment1 (month, year) | Last patient enrolment1 (month, year) | Date published (month, year) |
|---|---|---|---|---|---|---|---|---|
| Enrolment commenced before pandemic | ||||||||
| NCT00298233 | Phase 2 | Oseltamivir | 400 | 326 | 72 | Apr. 2007 | Feb. 2010 | May 2013 [8] |
| NCT00391768 | Phase 1/2 | Oseltamivir | 108 | 87 | 37 | Jan. 2007 | Apr. 2010 | Mar. 2013 [9] |
| Enrolment commenced during pandemic | ||||||||
| NCT00949533 | Phase 3 | Oseltamivir | 125 | 37 | Unknown | Aug. 2009 | Oct. 2010 | Apr. 2016 (Unp) |
| NCT00957996 | Phase 3 | Peramivir | 300 | 127 | 94 | Oct. 2009 | Oct. 2010 | Aug. 2013 [10] |
| NCT01199744 | Prospective cohort | Zanamivir | N/R | 1575 | Unknown | Nov. 2009 | Apr. 2010 | Mar. 2011(Unp) |
| NCT01014988 | Phase 2 | Zanamivir | 150 | 130 | 92 | Nov. 2009 | Sep. 2011 | Feb. 2014 [11] |
| NCT01052961 | Phase 4 | Oseltamivir | 400 | 155 | 34 | Jan. 2010 | Jun. 2012 | Dec. 2013 [12] |
| NCT01050257 | Phase 3 | Oseltamivir | 200 | 118 | Unknown | Jan. 2010 | Sep. 2012 | Aug. 2013 (Unp) |
| NCT01068912 | Phase 2 | Favipiravir | 384 | 530 | 110 | Feb. 2010 | May 2012 | Feb. 2014 (Unp) |
Enrolment number and publishing timeline for completed studies where results are published in the literature (date followed by reference) or on the clinical trials registration site (date followed by Unp)
N/R not reported
1Where conflict existed between numbers in the clinical trial record and publication, publication numbers were used